Thoratec takes Q2 loss but expands full-year projection

Despite a jump in device sales, Thoratec's ($THOR) second-quarter profits declined 2.8%, spurred by a 20% increase in operating expenses.

Thoratec's Q2 profits fell to $20.8 million, down from $21.8 million in the same period last year, and the increase in expenses came largely from investments in R&D.

Revenue, however, remains on the up and up, and Thoratec has increased the low end of its annual earnings projection by 4 cents, to $1.24 per share. The company also raised its full-year revenue projection to between $460 million and $470 million, up from the earlier-announced $452 million to $467 million.

Total sales increased by 6.8%, bringing in $118.7 million, and Thoratec's HeartMate line of ventricular pumps brought in $106.2 million on its own, an increase of 9%. The CentriMag blood pump saw its sales increase by 51%, to $8 million, while the company's long-running PVAD line of ventricular support devices declined 50%, to $3.8 million.

The HeartMate II pump, the latest generation in the line, saw its sales rise 13% on the quarter, despite a Class I recall in April. The pump forced Thoratec to issue new implantation instructions for the device after receiving 29 reports about a faulty component that could block blood flow if improperly installed.

In any case, the 6 months ending June 30 were the company's strongest in terms of revenue, CEO Gary Burbach said in a statement, and Thoratec is looking to expand its share in the ventricular assistance device market, plotting pivotal trials for HeartMate III and HeartMate PHP in 2013.

- read Thoratec's release
- get more from The Associated Press

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.